Scalper1 News
With tax-sheltering deals off the table for now, drugmakers have turned back to their traditional prey: hot biotech startups. But what investors want to know is: What kind of biotechnology are the startups looking for? One possible sign came in November, when big-cap biotech BioMarin Pharmaceutical (BMRN) agreed to pay $680 million for Prosensa Holding (RNA). Prosensa was preparing to file for approval of drisapersen, a treatment for Duchenne Scalper1 News
Scalper1 News